Genomic coordinate ( human 12:122,019,422 BCL7A).
Cytoband (human 12q24.31 BCL7A).
Intraband%= 33.7% BCL7A
OMIM’ genes @ 12q24.31 = 22 genes.
Polymorphs = 49 variants of BCL7A in ClinVar.
Hyperbolic Umbilic Chromosome-12 is 1,200 genes.
Here I 🎁 present: “BCL7A in High-grade B-Cell Lymphoma”, Victor McKusick, Mendelian Inheritance in Man’, 1966. (BCL7A)
INTRODUCTION.
In High-grade B-Cell Lymphoma (HGBL) and Diffuse Large B-Cell Lymphoma (DLBCL), the BCL7A gene acts primarily as a tumor suppressor. It encodes a crucial non-catalytic subunit of the SWI/SNF (BAF) chromatin remodeling complex, which regulates chromatin accessibility and gene expression.
Key aspects of BCL7A’s role in HGBL and DLBCL include:
- Genetic Alterations: The BCL7A gene frequently undergoes genomic deletions, epigenetic silencing, and recurrent point mutations (particularly biallelic inactivation and splice-site mutations) in aggressive B-cell lymphomas.
- Mechanism of Action: Truncating mutations in BCL7A’s N-terminal domain impair its ability to bind to the SWI/SNF complex. This loss-of-function hinders the complex’s capacity to properly regulate gene transcription and displace histones, thereby promoting lymphomagenesis.
- Chromosomal Translocations: BCL7A was originally identified as a gene involved in a complex, three-way chromosomal translocation involving MYC and IGH in high-grade non-Hodgkin lymphomas.
- Clinical Significance: Because BCL7A maintains a tumor-suppressive phenotype, its loss of expression is associated with altered B-cell activation, tumor progression, and aggressive lymphoma pathogenesis.
